SIM0709为集团基于自有多特异性抗体平台自主研发的长效人源化双特异性抗体。SIM0709可同时靶向 肿瘤坏死因子配体超家族成员15(TL1A)和白介素-23(IL-23)，从而阻断参与炎症性肠病发生及进展的两 条核心通路。SIM0709在体外原代细胞实验和体内动物实验中均表现出优异的药效协同效果，甚至优于 两个单药的联用。 智通财经APP讯，先声药业(02096)发布公告，于2026年1月26日，集团附属公司先声药业有限公司(江苏 先声)与勃林格殷格翰签署独家授权许可协议。根据该协议条款，勃林格殷格翰将获得用于炎症性肠病 的TL1A/IL-23p19双特异性抗体SIM0709在大中华区以外的全球独家权益。本次授权许可进一步验证了 集团自身免疫研发平台的创新性及领先性。 根据该协议条款，集团有权收取4200万欧元的首付款，以及基于研发进展、监管审批及商业化等情况， 最高达10.16亿欧元的里程碑付款。此外，集团亦有权就大中华区以外的净销售额收取分级特许权使用 费。 （原标题：先声药业(02096)与勃林格殷格翰就SIM0709(TL1A/IL-23p19双特异性抗体)订立独家授权许 可协议） ...

Core Viewpoint - The announcement by Xiansheng Pharmaceutical (02096) regarding the exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709 highlights the company's innovative and leading position in the field of autoimmune research [1] Group 1: Licensing Agreement Details - Xiansheng Pharmaceutical's subsidiary, Jiangsu Xiansheng, signed an exclusive licensing agreement with Boehringer Ingelheim on January 26, 2026, granting Boehringer exclusive rights to SIM0709 outside Greater China [1] - The agreement includes an upfront payment of €42 million and potential milestone payments up to €1.016 billion based on development progress, regulatory approvals, and commercialization [1] - The company will also receive tiered royalties on net sales outside Greater China [1] Group 2: Product Information - SIM0709 is a long-acting humanized dual-specific antibody developed on the company's proprietary multi-specific antibody platform [1] - The antibody targets both TNF superfamily member 15 (TL1A) and interleukin-23 (IL-23), blocking two key pathways involved in the onset and progression of inflammatory bowel disease [1] - SIM0709 has demonstrated superior synergistic efficacy in both in vitro primary cell experiments and in vivo animal studies, outperforming the combination of two single agents [1]

Core Viewpoint - The company Valiant Pharmaceuticals (维立志博-B, 09887) has seen a significant stock increase following the announcement of its core product, LBL-024, receiving orphan drug designation from the European Commission for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1: Product Development - LBL-024 has reached an important milestone in its global development process with the orphan drug designation [1] - The product is currently undergoing Phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, showcasing first-in-class (FIC) or best-in-class (BIC) potential [1] Group 2: Regulatory Approvals - On January 14, LBL-024 received Fast Track designation from the U.S. FDA for the treatment of extra-pulmonary neuroendocrine carcinoma [1] - LBL-024 is a bispecific antibody that targets both PD-L1 and 4-1BB, making it the first targeted therapy for 4-1BB receptor in the registration clinical stage for extra-pulmonary neuroendocrine carcinoma [1]

Core Viewpoint - The company, Valiant Bio (维立志博-B), has seen its stock price increase by over 4% following the announcement of its dual-specific antibody, LBL-024, receiving Fast Track designation from the FDA for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1 - Valiant Bio's LBL-024 has now received three regulatory recognitions, including Fast Track designation from the FDA, and is currently in Phase II or registration clinical trials for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC [1] - The Chief Medical Officer of Valiant Bio, Dr. Cai Shengli, emphasized that this latest recognition from an international regulatory authority highlights the significant clinical potential and market prospects of LBL-024 [1] - The milestone is expected to accelerate the global development process of LBL-024, facilitating its market entry and benefiting patients worldwide [1]

Core Viewpoint - The company Valiant Bio-B (09887) has received FDA fast track designation for its dual-specific antibody LBL-024, indicating significant clinical potential and market prospects for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1: Regulatory Approvals - LBL-024 has now received three regulatory recognitions, including fast track designation from the FDA for EP-NEC, and previous breakthrough therapy designation from China's NMPA and orphan drug designation from the FDA [1] - The drug is currently in phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, showcasing first-in-class (FIC) or best-in-class (BIC) potential [1] Group 2: Market Impact - The recognition from international regulatory authorities highlights the drug's substantial clinical potential and market outlook, which is expected to accelerate its global development process and expedite market entry [1] - The stock price of Valiant Bio-B increased by 4.26% to 56.3 HKD, with a trading volume of 3 million HKD, reflecting positive market sentiment following the announcement [1]

Core Insights - T-cell engagers (TCEs) are a focus in precision immunotherapy, showing rapid market growth and clinical advancements in cancer and autoimmune disease treatments [1][4] Market Overview - The global TCE market is projected to reach $5.6 billion by 2025 and $9.5 billion by 2026, with China's market expected to grow to $300 million and $600 million respectively [1][4] - Since 2024, the TCE sector has seen significant transaction activity, with 28 transactions recorded in 2024 and a total of 179 transactions from 2013 to 2024 [4][5] Clinical Trials - In 2024, there were 175 TCE clinical trials initiated globally, with 115 focused on hematological cancers, representing 65% of the market share [4] - The number of clinical trials for autoimmune diseases is expected to grow significantly, matching the 32 trials for solid tumors initiated in 2024 [4] Industry Definition and Classification - TCEs are a subgroup of immunotherapy that utilize bispecific antibodies to direct T-cells to kill tumor cells, classified into three main types: IgG-like TCEs, Fv-based TCEs, and combination-based TCEs [2][3] Industry Development - The development of TCEs has evolved over 40 years, from the initial concept in 1961 to clinical applications, with significant milestones in 1985 and 2008 marking key advancements [5][6] Competitive Landscape - Over ten TCEs have been approved globally, with a surge in approvals since 2022, particularly in the hematological cancer space [7] - Key companies involved in TCE development include Amgen, Roche, Johnson & Johnson, and several domestic firms in China such as Guangdong Fipeng Pharmaceutical and Aimi Biotechnology [7][8] Future Trends - TCEs are increasingly being explored for various diseases beyond hematological cancers, including autoimmune diseases, and are becoming a significant area of research in the biopharmaceutical sector [8][9]

Summary of Compass Therapeutics FY Conference Call Company Overview - **Company**: Compass Therapeutics (NasdaqCM:CMPX) - **Industry**: Oncology, specifically monoclonal antibody discovery and development - **Location**: Boston, Massachusetts - **Pipeline**: Four drugs in clinical development, with Tevesemig being the most advanced Key Points on Tevesemig - **Drug Description**: Tevesemig is a DLL4 VEGF A bispecific antibody, functioning as a next-generation angiogenesis inhibitor [1] - **Clinical Trials**: - Achieved primary endpoint in a randomized study for advanced biliary tract cancer [2] - Presented phase II data at ASCO GI showing monotherapy efficacy in advanced colorectal cancer [2] - Ongoing study COMPANION-002 comparing Tevesemig plus paclitaxel to paclitaxel alone in second-line treatment for advanced biliary tract cancer [6] - **Efficacy Data**: - Tevesemig tripled the overall response rate compared to control, with a complete response noted [7] - Significant difference in progression-free survival (PFS) observed, with 42.1% progression in control vs. 16.2% in combination arm at week eight [9] - More than 20% of patients alive at 18 months, compared to less than 10% in FOLFOX regimen [10] - **Market Opportunity**: - Estimated 25,000 new patients annually in the U.S. with biliary tract cancer, with a treatable population of approximately 15,000 [11] - Potential for over $1 billion annual market in second-line biliary tract cancer [11] - **Future Plans**: - Plans to expand indications post-approval, targeting other cancers like colorectal and gastric [12] - Potential to replace Avastin in various indications [13] Other Drug Developments - **CTX471**: - A CD137 agonist antibody showing nearly 30% response rate in post-PD1 melanoma patients [15] - Notable case of a patient with metastatic small cell lung cancer achieving a complete response after multiple therapies [16] - Planning an NCAM-positive basket study to explore efficacy further [17] - **CTX8371**: - A PD1/PDL1 bispecific antibody demonstrating unique T cell engagement and potential to convert PD1-positive T cells to PD1-negative [19] - Responses observed in patients with triple-negative breast cancer and Hodgkin's lymphoma [21] - Ongoing cohort expansions for further evaluation [21] - **CTX10726**: - A novel PD1/VEGF-A bispecific antibody entering clinical trials, showing superior preclinical efficacy compared to leading competitors [22][38] - Expected to initiate phase 1 study this quarter, with clinical data anticipated in the second half of the year [40] Commercialization Strategy - **Tevesemig**: - Plans to commercialize independently in the U.S. due to the specialized nature of the patient population [31] - Open to strategic partnerships for international markets [32] - **Infrastructure Development**: - Building commercial infrastructure over the next 12-18 months in preparation for drug launch [36] Conclusion - Compass Therapeutics is positioned for significant growth with its innovative pipeline, particularly Tevesemig, which has the potential to transform treatment for advanced biliary tract cancer and other malignancies. The company is actively preparing for commercialization and exploring further clinical opportunities across its drug portfolio.

Core Viewpoint - The company Valiant Biopharma-B (09887) has received Fast Track designation from the FDA for its PD-L1/4-1BB bispecific antibody, Valiant (Opatasumab, LBL-024), aimed at treating pulmonary neuroendocrine carcinoma, which accelerates the drug development process for serious conditions [1][2]. Group 1: Drug Development and Regulatory Milestones - Valiant is the first bispecific antibody targeting both PD-L1 and 4-1BB to reach the registration clinical stage for pulmonary neuroendocrine carcinoma [2]. - The Fast Track designation allows for more frequent regulatory interactions and the ability to submit a rolling New Drug Application (NDA) [1]. - The company has received Breakthrough Therapy Designation (BTD) from the NMPA for Valiant in treating advanced pulmonary neuroendocrine carcinoma, and Orphan Drug Designation (ODD) from the FDA for neuroendocrine carcinoma [2]. Group 2: Clinical Efficacy and Safety - In clinical trials in China, Valiant has shown promising efficacy signals and good safety profiles as both a monotherapy and in combination with chemotherapy for advanced pulmonary neuroendocrine carcinoma [2]. - The drug exhibits strong clinical activity potential in multiple indications, including non-small cell lung cancer, small cell lung cancer, and pulmonary neuroendocrine carcinoma [2]. - Valiant's design aims to overcome PD-1/L1 immune suppression and enhance T cell activation, indicating a broader cancer treatment potential compared to PD-1/L1 inhibitors [2]. Group 3: Broader Implications and Future Potential - 4-1BB as an agonist can reactivate exhausted T cells, making it suitable for treating "cold tumors" resistant to PD-1/PD-L1 therapies [3]. - Valiant has shown encouraging clinical signals in various cancers with unmet medical needs, including small cell lung cancer, cholangiocarcinoma, ovarian cancer, and triple-negative breast cancer [3]. - The drug is positioned to become a promising anti-tumor agent across a wide range of indications [3].

智通财经APP讯，维立志博-B(09887)发布公告，于2026年1月14日，PD-L1/4-1BB双特异性抗体维利信 (奥帕替苏米单抗，LBL-024)获美国食品药品监督管理局(FDA)授予快速通道资格认定，用于治疗肺外 神经内分泌癌。 在中国的两项临床试验中，维利信不论作为单药疗法或与化疗联合使用，均对晚期肺外神经内分泌癌患 者表现出令人鼓舞的疗效信号且安全性良好。本公司于2024年4月获得国家药品监督管理局(NMPA)批准 开展单臂注册临床试验，于2024年10月自NMPA获得维利信TM治疗后线晚期肺外神经内分泌癌的突破 性疗法认定(BTD)，于2024年11月自FDA获得治疗神经内分泌癌的孤儿药认定(ODD)。 4-1BB作为激动剂，能够重新激活凋亡的T细胞并大量扩增，特别适合治疗PD-1/PD-L1耐药或无效的"冷 肿瘤"。除肺外神经内分泌癌外，维利信在有大量未满足医疗需求的多个癌种中展现出令人鼓舞的临床 信号，包括小细胞肺癌、胆道癌、卵巢癌、非小细胞肺癌、食管鳞状细胞癌、肝细胞癌、胃癌、叁阴性 乳腺癌及黑色素瘤，并已在小细胞肺癌、胆道癌及卵巢癌等多个癌种中观察到令人振奋的临床效果，有 望成为一款具 ...

Core Viewpoint - The company has received FDA fast track designation for its bispecific antibody, ViliXinTM (Opa-Tisumi Monoclonal Antibody, LBL-024), for the treatment of pulmonary neuroendocrine carcinoma, indicating significant potential in addressing unmet medical needs in oncology [1][2] Group 1: FDA Designation and Drug Development - ViliXinTM has been granted fast track designation by the FDA, which accelerates the review process for drugs that treat serious conditions or fill unmet medical needs [1] - The fast track designation allows for more frequent regulatory interactions and the ability to submit a rolling new drug application [1] Group 2: Clinical Trial Results - In clinical trials in China, ViliXinTM has shown encouraging efficacy signals and good safety profiles as both a monotherapy and in combination with chemotherapy for patients with advanced pulmonary neuroendocrine carcinoma [2] - The company received approval from the National Medical Products Administration (NMPA) in April 2024 to conduct a single-arm registration clinical trial and was granted breakthrough therapy designation (BTD) in October 2024 [2] Group 3: Broader Implications and Potential - ViliXinTM targets both PD-L1 and 4-1BB, showing potential as the first approved drug for advanced pulmonary neuroendocrine carcinoma and demonstrating first-in-class or best-in-class clinical activity in various indications [1] - The drug has also shown promising clinical signals in multiple cancers with high unmet medical needs, including small cell lung cancer, cholangiocarcinoma, ovarian cancer, non-small cell lung cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, gastric cancer, triple-negative breast cancer, and melanoma [2]